Hydroxyproline sales will rise through 2036, driven by pharmaceutical grade at 61.0% of the form segment in 2026. Pharmaceutical intermediate holds a 33.0% share of demand. The market was valued at USD 85.7 million in 2026 and is expected to reach USD 140.9 million by 2036 across global demand.